Related Experiment Video
Updated: Mar 1, 2026
Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements
Published on: January 7, 2019
Interaction Between the Cannabinoid and Vanilloid Systems on Anxiety in Male Rats
Nafiseh Faraji1,2, Alireza Komaki1, Iraj Salehi1
1Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.
Introduction:
Previous studies have shown that the cannabinoid system is involved in anxiety. In addition, transient receptor potential vanilloid type-1 (TRPV1) channels are new targets for the development of anxiolytics. The present study investigated the possible interaction between the cannabinoid and vanilloid systems on anxiety-like behavior in rats.
Methods:
Four different groups of male Wistar rats received intraperitoneal (IP) injections of (1) vehicle (DMSO+saline), (2) cannabinoid receptor agonist WIN55212-2 (WIN) (1 mg/kg), (3) TRPV1 receptor antagonist capsazepine (CPZ) (5 mg/kg), or (4) combined WIN (1 mg/kg) and CPZ (5 mg/kg) treatment 30 minutes before testing in the elevated plus maze.
Results:
The results showed that compared to the control (vehicle), both WIN and CPZ increased the time spent and number of entries on the open arms. Co-administration of WIN and CPZ had a synergistic effect, i.e., the number of entries and time spent on the open arms was greater than that in the groups administered the two compounds alone. The total distance travelled by rats and total number of entries on to the arms did not significantly differ between groups.
Conclusion:
Acute neuropharmacological blockade of the TRPV1 receptor or stimulation of the CB1 receptor produced an anxiolytic effect. It seems that antagonism of the vanilloid system modulates cannabinoid gain that rises the anxiolytic effect. TRPV1 antagonism may amend generation of endocannabinoids, which in turn increases anxiolytic impact. These results suggest that two systems could act on or share a common signaling pathway affecting the expression of anxiety.
Insights
Blocking TRPV1 receptors or stimulating cannabinoid receptors reduces anxiety-like behavior in rats. Combining these treatments synergistically enhances the anxiolytic effect, suggesting a shared pathway for anxiety regulation.
Area of Science:
- Neuropharmacology
- Anesthesiology
- Behavioral Neuroscience
Background:
- The endocannabinoid system plays a role in regulating anxiety.
- Transient receptor potential vanilloid type-1 (TRPV1) channels are emerging targets for anxiolytic drug development.
- Understanding the interplay between cannabinoid and vanilloid systems is crucial for novel anxiety treatments.
Purpose of the Study:
- To investigate the interaction between cannabinoid and vanilloid systems in modulating anxiety-like behavior in a rat model.
- To determine the anxiolytic potential of targeting TRPV1 channels and cannabinoid receptors.
Main Methods:
- Male Wistar rats were administered intraperitoneal injections of a cannabinoid receptor agonist (WIN55212-2), a TRPV1 receptor antagonist (capsazepine), or a combination thereof, along with vehicle controls.
- Anxiety-like behavior was assessed using the elevated plus maze test.
- Behavioral parameters including time spent and entries on open arms were recorded.
Main Results:
- Both WIN55212-2 and capsazepine administration individually increased exploration of the open arms, indicating an anxiolytic effect.
- Co-administration of WIN55212-2 and capsazepine resulted in a synergistic anxiolytic effect, significantly greater than either compound alone.
- No significant differences in total distance traveled or total arm entries were observed, suggesting the effects were specific to anxiety-like behavior.
Conclusions:
- Acute blockade of TRPV1 receptors or stimulation of cannabinoid receptors exhibits anxiolytic properties in rats.
- Antagonism of the vanilloid system appears to potentiate the anxiolytic effects of cannabinoid system modulation, possibly by influencing endocannabinoid generation.
- These findings suggest a potential shared signaling pathway between the cannabinoid and vanilloid systems in the regulation of anxiety.
Related Concept Videos
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
01:18Anxiety: Overview
Individuals with anxiety often experience a range of physical and emotional symptoms, including sweating, trembling, tachycardia, and disturbances in sleep patterns. These symptoms vary in intensity and frequency but are generally disruptive and distressing.
01:26Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...